HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbalife Turning A New Leaf While An Old Opponent Folds His Tent

This article was originally published in The Rose Sheet

Executive Summary

Direct seller Herbalife has a new capital allocation strategy and will ask shareholders for a new name and two-for-one split of its stock. It also has lost an old opponent as hedge fund manager and activist investor William Ackman sheds his investment that would have paid off if Herbalife had gone under.

You may also be interested in...

Herbalife Compensates Following Regulatory Scrutiny, Icahn's Takeover Play

Revamped compensation practices Herbalife agreed to implement as part of a settlement to end the FTC investigation are starting to bear fruit, says Co-President John DeSimone. Investor Carl Icahn, meanwhile, sold a large slice of his stake in the firm's recent share buy-back tender, ending this takeover leverage while remaining the largest shareholder.

CBD Cancer Claim Gets NAD Attention: Health And Wellness News

NAD sends CBD oil cancer claim to FTC; Supplement OWL passes 10,000 at first anniversary; Herbalife Nutrition two-for-one stock split; and Après resumes shipping with funding.

GNC Credit, Herbalife Q4, Industry Summit: Health And Wellness News

GNC approaches closing $300m Hayao investment with lenders' OK to re-work loans; Herbalife back to sales growth and prepares for management changes; and CFSAN's Education Resource Library is accessible as a catalog of nearly 300 publications and videos.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts